Early results from the largest ever randomised trial for lung cancer, using a blood test that detects autoantibody biomarkers, will be released on 7th September at the International Association for the Study of Lung Cancer’s 16th World Conference on Lung Cancer.
Cambridge Radiotherapy Index helps select patients who will benefit from radiotherapy following mastectomy for early breast cancer.
Pre-operative (neoadjuvant) chemotherapy trial confirms that sequencing of chemotherapy drugs has a significant impact on response to chemotherapy.
Until now, proof of causation in cases of breast cancer delay has relied on being able to show that a delay in treatment has reduced the prospects of 10-year survival from above 50% to below 50%.
Alcohol is now recognised as a significant risk factor for the development of breast cancer and the increased risk is directly proportional to the amount of alcohol consumed.
Professor Gordon C Wishart recently talked to News Medical about a new and innovative method for sentinel lymph node biopsy in breast and other cancers.
Ductal carcinoma in situ (DCIS), a non-spreading type of breast cancer, constitutes a major public health problem, and now represents up to half of the cases detected by breast screening.
The use of intensity modulated radiotherapy (IMRT) in early breast cancer allows an even distribution of the radiotherapy dose to be delivered to the entire breast target.